Otros idiomas Cocrystal Pharma, Inc.

Acciones

COCP

US19188J4094

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 01/07/2024			Varia. Cinco días.	Varia. 1 de enero.
2,4 ^USD	+3,00 %		-8,05 %	+39,36 %

20/06	Cocrystal Pharma avanza el Cc-42344 en un estudio de fase 2A contra la gripe A y espera resultados de primera línea a finales de 2024	CI
13/05	Cocrystal Pharma, Inc. Resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows	20/06
Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024	20/06
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	13/05
Cocrystal Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza	01/05
Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects	01/05
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	28/03
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A	19/03
Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates	04/01
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates	04/01
Top Premarket Gainers	07/12
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A	06/12
Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A	06/12
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	29/11
Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast	29/11
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023	27/11
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	13/11
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	09/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Cocrystal Pharma, Inc.

Acciones

COCP

US19188J4094

Otros idiomas

Filtros